Breast cancer is a highly heterogeneous disease, which is clinically stratified based on the expression of ER, progesterone receptor (PR), and HER2 into three broad clinical groups that correlate with prognosis and treatment strategies: ER+, HER2+, and triple-negative breast cancer (TNBC)7. This evidence concerns the gene PGR and triple-negative breast carcinoma.